As our loyal readers know, your bloggers like to keep an eye on advances affecting our drug and device clients – and take particular interest in the product liability implications of such advances.

Which brings us to pharmacogenomics, the study of how human genetic information impacts drug response. Rapid advances in our understanding of this area mean we now know that genetic differences between individuals can affect everything from the drug or drug class most likely to provide benefit to the likelihood of drug toxicity.

Pharmacogenomics is already affecting product liability litigation, and we’d place our bets on further impact being just around the corner. That’s why Bexis and frequent guest blogger/Reed Smith associate Matt Jacobson are presenting a free, 60-minute webinar on “Pharmacogenomics and Product Liability: What’s Already Happened, and What’s Just Around the Corner” on April 5 at 3 p.m. ET.

This webinar is presumptively approved for 1.0 general CLE credit in California, Illinois, New Jersey, Pennsylvania, Texas and West Virginia. For lawyers licensed in New York, this course is eligible for 1.0 credit under New York’s Approved Jurisdiction Policy.

The program is free and open to anyone interested in tuning in, but you do have to sign up, which you can do here.